Acta Neuropharmacologica››2018,Vol. 8››Issue (1): 1-8.DOI:10.3969/j.issn.2095-1396.2018.01.001
DU Guan-hua，ZHANG Wen，DU Li-da，MA Yin-zhong，LI Li，WANG Yue-hua
Online:2018-02-26Published:2018-06-04Contact:杜冠华，男，博士生导师；研究方向：神经药理与新药发现；Tel：+86-010-63165184，E-mail：dugh@imm.ac.cnSupported by:
中国医学科学院协同创新工程（No.2017-I2M-1-010），国家自然科学基金项目（No.81603100）
CLC Number:
DU Guan-hua，ZHANG Wen，DU Li-da，MA Yin-zhong，LI Li，WANG Yue-hua.New Strategies for the Drug Development of Anti-cerebral Ischemia
—Advances in the Etiology and Drug Development of Acute Cerebral Ischemia[J]. Acta Neuropharmacologica, 2018, 8(1): 1-8.
| [1] 陈伟伟, 高润霖, 刘力生, 等.《中国心血管病报告2016》概要[J]. 中国循环杂志, 2017, 32(6): 617-622. [2] Richard H Swartz, Mark Bayley, Krista L Lanctôt, et al. Post-stroke depression, obstructive sleep apnea, and cognitive impairment: rationale for, and barriers to, routine screening[J]. Int J Stroke, 2016, 11(5): 509-518. [3] Guzik Amy, Bushnell Cheryl. Stroke epidemiology and risk factor management [J]. Continuum (Minneap Minn), 2017, 23(1, Cerebrovascular Disease): 15-39. [4] Mark J Alberts. Stroke treatment with intravenous tissue-type plasminogen activator[M]. Am Heart Assoc, 2017, 135(2):140-142. [5] Adams H P, Adams R J, Brott T, et al. Guidelines for the early management of patients with ischemic stroke[J]. Stroke, 2003, 34(4): 1056-1083. [6] 瓮长水, 孙启良.《日本脑卒中治疗指南》(2004’) 康复部分简介[J]. 中国康复医学杂志, 2005, 20(7): 534-538. [7] 中华医学会神经病学分会. 中国急性缺血性脑卒中诊治指南2014[J]. 中华神经科杂志, 2015, 48(4): 246-257. [8] Xu Sui-yi, Pan Su-yue. The failure of animal models of neuroprotection in acute ischemic stroke to translate to clinical efficacy[J]. Med Sci Monit Basic Res, 2013, 19(19): 37-45. [9] Marc Fisher. New approaches to neuroprotective drug development[J]. Stroke, 2011, 42(1 suppl 1): S24-S27. [10] Angel Chamorro, Ulrich Dirnagl, Xabier Urra, et al. Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation[J]. The Lancet Neurology, 2016, 15(8): 869-881. [11] Stephen Grupke, Jason Hall, Michael Dobbs, et al. Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: from review to preview[J]. Clin Neurol Neurosurg, 2015, 129: 1-9. [12] Kaste M. Is there a future for neuroprotective agents in acute ischaemic stroke?[J]. Eur J Neurol, 2012, 19(6): 797-798. [13] Jens Minnerup, Heike Wersching, Matthias Schilling, et al. Analysis of early phase and subsequent phase III stroke studies of neuroprotectants: outcomes and predictors for success[J]. Exp Transl Stroke Med, 2014, 6(1): 2. [14] Zhang Qing-hua, Wang Chao, Zheng Mao-yong, et al. Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis[J]. Cerebrovasc Dis, 2015, 39(1): 13-22. [15] Pierre Amarenco, Julien Labreuche. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention[J]. Lancet Neurol, 2009, 8(5): 453-463. [16] Muzamil Ahmad, Nawab John Dar, Zubair Shanib Bhat Z, et al. Inflammation in ischemic stroke: mechanisms, consequences and possible drug targets[J]. CNS Neurol Disord Drug Targets, 2014, 13(8): 1378-1396. [17] Tomasz Dziedzic. Systemic inflammation as a therapeutic target in acute ischemic stroke[J]. Expert Rev Neurother, 2015, 15(5): 523-531. [18] Zhang Rong-rong, Xu Meng-xue, Wang Yu, et al. Nrf2-a promising therapeutic target for defensing against oxidative stress in stroke[J]. Mol Neurobiol, 2017, 54(8): 6006-6017. [19] Dang Bao-qi, Duan Xiao-chun, Wang Zhong, et al. A therapeutic target of cerebral hemorrhagic stroke: matrix metalloproteinase-9[J]. Curr Drug Targets, 2017, 18(12): 1358-1366. [20] Rafael Andres Posada-Duque, George E Barreto, Gloria Patricia Cardona-Gomez. Protection after stroke: cellular effectors of neurovascular unit integrity[J]. Front Cell Neurosci, 2014, 8(231): 231. [21] Gorelick P, Grotta J, Greenwood D, et al. Recommendations for clinical trial evaluation of acute stroke therapies-Stroke Therapy Academic Industry Roundtable II (STAIR-II)[J]. Stroke, 2001, 32(7): 1598-1606. [22] Mrac Fisher. Recommendations for advancing development of acute stroke therapies[J]. Stroke, 2003, 34(6): 1539-1546. [23] Marc Fisher, Daniel F Hanley, George Howard, et al. Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes[J]. Stroke, 2007, 38(2): 245-248. [24]Marc Fisher. Enhancing the development and approval of acute stroke therapies[J]. Stroke, 2005, 36(8): 1808-1813. [25] Marc Fisher, Giora Zeev Feuerstein, David W Howells, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations[J]. Stroke, 2009, 40(6): 2244-2250. [26] Jeffrey L Saver, Gregory W Albers, Billy Dunn, et al. Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials[J]. Stroke, 2009, 40(7): 2594-2600. [27] Saver J L, Jovin T G, Smith W S, et al. Stroke treatment academic industry roundtable [J]. Stroke, 2013, 44(12): 3596-3601. [28] Jovin T G, Albers G W, Liebeskind D S, et al. Stroke Treatment Academic Industry Roundtable[J]. Stroke, 2016, 47(10): 2656-2665. [29]Karin E Sandoval, Ken A Witt. Blood-brain barrier tight junction permeability and ischemic strok[J]. Neurobiol Dis, 2008, 32(2): 200-219. [30] Liu Jia-ling, Wang Yong-ting, Yosuke Akamatsu, et al. Vascular remodeling after ischemic stroke: mechanisms and therapeutic potentials[J]. Prog Neurobiol, 2014, 115: 138-156. [31] Peter M Rothwell, Ale Algra, Chen Zheng-ming, et al. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials[J]. Lancet, 2016, 388(10042): 365-375. [32] Mora S, Ames J M, Manson J E. Low-dose aspirin in the primary prevention of cardiovascular disease: shared decision making in clinical practice[J]. JAMA, 2016, 316(7): 709-710. [33] Praful M Dalal, Madhumita Bhattacharjee. Stroke epidemic in India: hypertension-stroke control programme is urgently needed[J]. J Assoc Physicians India, 2007, 55:689-691. [34] Funaki S, Tokutomi F, Wada-Takahashi S, et al. Porphyromonas gingivalis infection modifies oral microcirculation and aortic vascular function in the stroke-prone spontaneously hypertensive rat (SHRSP)[J]. Microb Pathog, 2016, 92: 36-42. [35] Joon-Tae Kim, Gregg C Fonarow, Eric Smith, et al. Treatment with tPA in the "golden hour" and the shape of the 4.5 hour time-benefit curve in the national US Get With the Guidelines-Stroke population[J]. Circulation, 2016,. 135(2): 128-139. [36] Wang Meng-die, Yin Xiao-xv, Yang Ting-ting, et al. Chinese neurologists’ perspective on intravenous thrombolysis for acute ischemic stroke[J]. Brain Behav, 2017, 8(1):e00882. [37] Wang Yi-long, Liao Xiao-ling, Zhao Xing-quan, et al. Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China[J]. Stroke, 2011, 42(6): 1658-1664. [38] Yang Yi, Gary A Rosenberg. Blood–brain barrier breakdown in acute and chronic cerebrovascular disease[J]. Stroke, 2011, 42(11): 3323-3328. [39] Raymond Shim, Connie H Y Wong. Ischemia, immunosuppression and infection-tackling the predicaments of post-stroke complications[J]. Int J Mol Sci, 2016, 17(1): 551-556. [40] Rebecca A Harrison, Thalia Shoshana Field. Post stroke pain: identification, assessment, and therapy[J]. Cerebrovasc Dis, 2015, 39(3-4): 190-201. [41] 马寅仲, 李莉, 孔令雷, 等. 匹诺塞林对大鼠脑梗死后rtPA诱导的出血性转化的预防作用及机制[J]. 中国药理学与毒理学杂志, 2016, 30(10): 1017 [42] Gao Mei, Zhu Shen-yin, Tan Chu-bing, et al. Pinocembrin protects the neurovascular unit by reducing inflammation and extracellular proteolysis in MCAO rats[J]. J Asian Nat Prod Res, 2010, 12(5): 407-418. [43] Meng Fan-rui, Liu Rui, Gao Mei, et al. Pinocembrin attenuates blood-brain barrier injury induced by global cerebral ischemia-reperfusion in rats[J]. Brain Res, 2011, 1391: 93-101. [44] Shi L L, Chen B N, Gao M, et al. The characteristics of therapeutic effect of pinocembrin in transient global brain ischemia/reperfusion rats[J]. Life Sci, 2011, 88(11-12): 521-528. [45] Wang S B, Pang X B, Gao M, et al. Pinocembrin protects rats against cerebral ischemic damage through soluble epoxide hydrolase and epoxyeicosatrienoic acids[J]. Chin J Nat Med, 2013, 11(3): 207-213. [46] Wu Cai-xia, Liu Rui, Gao Mei, et al. Pinocembrin protects brain against ischemia/reperfusion injury by attenuating endoplasmic reticulum stress induced apoptosis[J]. Neurosci Lett, 2013, 546: 57-62. [47] Zhao Gang, Zhang Wen, Li Li, et al. Pinocembrin protects the brain against ischemia-reperfusion injury and reverses the autophagy dysfunction in the penumbra area[J]. Molecules, 2014, 19(10): 15786-15798. [48] Gregory J Del Zoppo, Jeffrey L Saver, Edward C Jauch, et al. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator[J]. Stroke, 2009, 40(8): 2945-2948. [49] Yoshihiro Murata, Anna Rosell, Robert H Scannevin, et al. Extension of the thrombolytic time window with minocycline in experimental stroke[J]. Stroke, 2008, 39(12): 3372-3377. [50] Chamila Geeganage, Philip MW Bath. Vasoactive drugs for acute stroke[J]. Cochrane Database Syst Rev, 2010, 7: CD002839. [51] M Ihsan Kaadan, Mary Jo Larson. Management of post-stroke depression in the Middle East and North Africa: Too little is known[J]. J Neurol Sci, 2017, 378: 220-224. |
| [1] | SUN Yi，TAN Bo，SU Rui-bin.Biased Ligand——Novel Paradigm for Opioid Analgesics[J]. Acta Neuropharmacologica, 2018, 8(2): 1-7. |
| [2] | WANG Jin-hui，HUANG Li，CHEN Na.Ischemic Injury of Cortical GABAergic Neurons：Vulnerability，Mechanism and Pathological Impacts[J]. Acta Neuropharmacologica, 2018, 8(2): 8-25. |
| [3] | LIN Zhi-bin.Pharmacological Progress of Ganoderma on Anti-aging and Anti-Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2018, 8(1): 9-15. |
| [4] | MA Juan，ZHANG Fa-li，QIAN Zhong-ming.Hepcidin and Iron-associated Neurodegenerative Disorders[J]. Acta Neuropharmacologica, 2018, 8(1): 16-22. |
| [5] | YANG Yan-fei，HUANG Zhi-li.Recent Advance on Sleep-Wake Regulation Based on Novel Techniques for Specific Manipulations of Neuron Activities[J]. Acta Neuropharmacologica, 2018, 8(1): 23-34. |
| [6] | WANG Yun，ZHEN Xue-chu.An Update on Allosteric Modulator of Sigma-1 Receptors: Potential Applications[J]. Acta Neuropharmacologica, 2018, 8(1): 35-44. |
| [7] | ZAN Gui-ying，SUN Xiang，LI Qing-lin，LIU Jing-gen.Research Progress of the Role and Underlying Mechanism of Dynorphin/κ Opioid Receptor in the Development of Depression[J]. Acta Neuropharmacologica, 2018, 8(1): 54-64. |
| [8] | ZHANG Kuo，YANG Jing-yu，WU Chun-fu.Progress on Pathophysiology and Animal Models of Depression[J]. Acta Neuropharmacologica, 2017, 7(4): 8-16. |
| [9] | REN Jing，ZHANG Dan-shen.Progress in Research of Brain Targeting Ligand for Nano-scale Drug Delivery Systems[J]. Acta Neuropharmacologica, 2017, 7(4): 17-25. |
| [10] | PANG Xue-bo，XUE Qian，ZOU Yu-an.The Research Progress of Plasma Lipoprotein-associated Phospholipase A2 and Ischemic Stroke[J]. Acta Neuropharmacologica, 2017, 7(4): 31-35. |
| [11] | WAN Ye，GUO Chun-yan，LI Yong-min.Research Progress of Traditional Chinese Medicine in Parkinson’s Disease[J]. Acta Neuropharmacologica, 2017, 7(4): 36-42. |
| [12] | WANG Cui, GUO Tong-lin, SHEN Li-xia.Study on the Neuroprotective Effects of Phytoestrogens in Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2017, 7(4): 43-52. |
| [13] | BAI Yan-chang，JIA Yan-li，SONG Ya-xue，WANG Jian-hua.Advance of Functional Magnetic Resonance Imaging of Brain in Alzheimer’s Disease[J]. Acta Neuropharmacologica, 2017, 7(3): 6-11. |
| [14] | REN Qian,WANG Zhen-zhen,CHEN Nai-hong.Regulation of Neuroplasticity by MicroRNA in Depression Disorder[J]. Acta Neuropharmacologica, 2017, 7(3): 12-20. |
| [15] | HUANG Qian，SUN Ming-li，LI Teng-fei，WANG Yong-xiang.Research Progress on Mechanisms Underlying Aconitines Analgesia[J]. Acta Neuropharmacologica, 2017, 7(3): 21-32. |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
